Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Leases (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Leases for 7 consecutive years, with $650000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases changed N/A to $650000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $650000.0, a N/A change, with the full-year FY2025 number at $650000.0, changed N/A from a year prior.
  • Current Leases was $650000.0 for Q4 2025 at Rhythm Pharmaceuticals, up from $624000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $816000.0 in Q2 2024 to a low of $224000.0 in Q1 2025.
  • A 5-year average of $638888.9 and a median of $647000.0 in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: rose 13.55% in 2021, then crashed 71.75% in 2025.
  • Rhythm Pharmaceuticals' Current Leases stood at $606000.0 in 2021, then grew by 12.87% to $684000.0 in 2022, then grew by 12.57% to $770000.0 in 2023, then rose by 5.97% to $816000.0 in 2024, then fell by 20.34% to $650000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Current Leases are $650000.0 (Q4 2025), $624000.0 (Q3 2025), and $510000.0 (Q2 2025).